Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 392 participants.

Also called NCT02944734

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 392 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02944734
Other papers using this trial's data
  • Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial Clinical therapeutics, 2017-08 DOI, PubMed 28734660

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02944734. Randomized; quadruple masking; primary purpose treatment. Start 2014-09 (registry gives no type); primary completion 2015-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
Candesartan Cilexetil 8mg
Intervention (Drug)
Candesartan Cilexetil 16mg
Intervention (Drug)
Amlodipine 5mg
Intervention (Drug)
Amlodipine 10mg
Lead sponsor
Shin Poong Pharmaceutical Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02944734
Content hash
9b3bae408541b66ae52eae325e024b120f653a2a95dfc8e8db8a7f15fcfe20ab